Previous studies have suggested that ANXA2 is highly upregulated in many malignant tumors, including breast cancer, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma and pancreatic ductal adenocarcinoma [26–30]. Here, ANXA2 is linked to hepatocellular carcinoma.